Table 1.
Characteristics of the study population with SARS-CoV-2 infection.
| n = 100 | |
|---|---|
| Age at COVID-19 diagnosis (years) median (IQR) | 46.5 (33.5, 52.8) |
| BMI, kg/m2 Median (IQR) | 24.2 (21.9, 28.1) |
| Sex, n (%) | |
| female | 77 (77) |
| male | 23 (23) |
| Occupation, n (%) | |
| Physician or paramedical staff | 74 (74) |
| Others | 26 (26) |
| Comorbidities, n (%) | |
| No comorbidities | 53 (53) |
| allergy | 29 (29) |
| hypertension | 14 (14) |
| autoimmune diseases | 13 (3) |
| asthma | 5 (5) |
| cancer | 3 (3) |
| diabetes | 3 (3) |
| heart disease | 2 (2) |
| Reported Symptoms, n (%) | |
| No symptoms | 16 (16) |
| asthenia | 57 (57) |
| anosmia | 55 (55) |
| muscle ache | 53 (53) |
| fever | 52 (52) |
| ageusia | 49 (49) |
| headache | 47 (47) |
| cough | 44 (44) |
| diarrhea | 35 (35) |
| runny nose | 28 (28) |
| dyspnea | 24 (24) |
| chest pain | 22 (22) |
| skin manifestations | 14 (14) |
| palpitations | 13 (13) |
| Severity, n (%) | |
| asymptomatic | 16 (16) |
| symptomatic | 74 (74) |
| hospitalized | 10 (10) |
| Median (IQR) days between positive PCR and first antibody test (M2) | 51 (43, 56) |
| Median (IQR) days between positive PCR and second antibody test (M10) | 293 (287, 303) |
| Vaccinated (among 71 subjects with second antibody test), n (%) | 36 (50.7) |
| One dose, n (%) | 21 (29.6) |
| Two doses, n (%) | 15 (21.1) |
| Median (IQR) days between vaccination (single dose) and second antibody test (M10) | 15 (11, 18) |
| Median (IQR) days between vaccination (second dose) and second antibody test (M10) | 8 (3, 10) |